EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study

Xi Ding, Wei-Jing Zhang, Rui You, Xiong Zou, Zhi-Qiang Wang, Yan-Feng Ouyang, Lan Peng, You-Ping Liu iD, Chong-Yang Duan iD, Qi Yang, Chao Lin, Yu-Long Xie und 8 weitere

Journal of Clinical Oncology · 10.05.2023 · 41 (14) · 2571-2582

DOI: 10.1200/jco.22.01450 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2023. Verfasst von Xi Ding und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Immune checkpoint inhibitors combined with antiangiogenic therapy reportedly have potential synergistic antitumor activity. We investigated the activity and safety of this regimen for recurrent/metastatic nasopharyngeal carcinoma (NPC). METHODS This single-arm, Simon two-stage study enrolled patients with recurrent/metastatic NPC who were refractory to at least first-line systemic therapy and treatment-naive to immune checkpoint inhibitors. The patients received camrelizumab 200 mg once every 3 weeks and apatinib 250 mg once per day. The primary end point was the objective response rate. Key secondary end points included disease control rate, progression-free survival, duration of response, overall survival, and safety. RESULTS Between October 14, 2020, and December 23, 2021, 58 patients were enrolled, and all were included in the efficacy and safety analysis set. The objective response rate was 65.5% (95% CI, 51.9 to 77.5), and the disease control rate was 86.2% (95% CI, 74.6 to 93.9). The median duration of response was not reached, and the median progression-free survival was 10.4 months (95% CI, 7.2 to 13.6), with a median follow-up duration of 12.4 months (range, 2.1-19.9 months). Treatment-related adverse events (TRAEs) of grade 3 or higher were reported in 34 (58.6%) patients, with the most common being hypertension (19.0%), nasopharyngeal necrosis (15.5%), headache (12.1%), AST elevation (10.3%), and creatine phosphokinase elevation (10.3%). Sixteen (27.6%) patients discontinued apatinib treatment before progression because of unbearable TRAEs, and the most common complication was nasopharyngeal necrosis (9/16; 56.3%). Recurrent nasopharyngeal lesions (odds ratio, 5.94 [95% CI, 1.45 to 24.24]) and reirradiation (odds ratio, 5.33 [95% CI, 1.15 to 24.79]) were significantly positively correlated with nasopharyngeal necrosis. CONCLUSION Camrelizumab plus apatinib had promising antitumor activity in patients with refractory recurrent/metastatic NPC who failed first-line therapy. Moderate to severe TRAEs were experienced by 58.6%, including nasopharyngeal necrosis associated with local recurrence and a history of reirradiation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNasopharyngeal NeoplasmsHumansNasopharyngeal CarcinomaNeoplasm Recurrence, LocalNecrosisAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedPyridines

Substanzen

Immune Checkpoint InhibitorscamrelizumabAntibodies, Monoclonal, HumanizedapatinibPyridines

Autor:innen und Institutionen

  • Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P.R. China.
  • Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, P.R. China.
  • Department of Medical Imaging, Sun Yat-sen University Cancer Center, Guangzhou, P.R. China.
  • Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, Kunming, P.R. China.
  • Department of Biostatistics, School of Public Health, Southern Medical University, Guangzhou, P.R. China.

ORCID-Profile: You-Ping Liu, Chong-Yang Duan, Yong-Long Liu, Ming-Yuan Chen

Zitieren

APA

Ding, X., Zhang, W. J., You, R., Zou, X., Wang, Z. Q., Ouyang, Y. F., Peng, L., Liu, Y. P., Duan, C. Y., Yang, Q., Lin, C., Xie, Y. L., Chen, S. Y., Liu, Y. L., Gu, C. M., Xie, R. Q., Huang, P. Y., Hong, M. H., Hua, Y. J., & Chen, M. Y. (2023). Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 41(14), 2571-2582. https://doi.org/10.1200/jco.22.01450

Vancouver

Ding X, Zhang WJ, You R, Zou X, Wang ZQ, Ouyang YF, et al. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology. 2023;41(14):2571-2582. doi:10.1200/jco.22.01450

BibTeX
@article{Ding2023,
  author = {Ding, Xi and Zhang, Wei-Jing and You, Rui and Zou, Xiong and Wang, Zhi-Qiang and Ouyang, Yan-Feng and Peng, Lan and Liu, You-Ping and Duan, Chong-Yang and Yang, Qi and Lin, Chao and Xie, Yu-Long and Chen, Si-Yuan and Liu, Yong-Long and Gu, Chen-Mei and Xie, Ruo-Qi and Huang, Pei-Yu and Hong, Ming-Huang and Hua, Yi-Jun and Chen, Ming-Yuan},
  title = {Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {14},
  pages = {2571--2582},
  doi = {10.1200/jco.22.01450}
}
Kostenlos starten →